Gilead buying another NASH program for up to $470m
This article was originally published in Scrip
Gilead Sciences has two market-leading drugs to treat hepatitis C and now the company is expanding its liver disease empire with the acquisition of small molecules for the treatment of non-alcoholic steatohepatitis (NASH) from Phenex Pharmaceuticals.
You may also be interested in...
With hepatitis C wrapped up, NASH is becoming the focus of liver disease R&D. Gilead, which has a number of NASH programs, has paid Phenex $100m for clinical progress with an in-licensed candidate for NASH and other liver diseases.
Public Company Edition: Drug developers continue to take advantage of investors’ preference for biotechnology investments, with CRISPR, Acceleron and BioNTech raising massive sums. The wealth isn’t spreading to everyone, however, as DBV Technologies is restructuring and cutting jobs.
Private Company Edition: BioGeneration closed a €105m ($119m) fund to continue backing new European companies, while Samsara BioCapital, Evotec and KCK Ltd. launched the virtual incubator Autobahn Labs. Also, Poseida, Annexon and Goldfinch close $100m-plus VC rounds.